Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948174 | 1.00 | KCNH2 (0.38) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12404476 | 0.96 | KCNH2 (0.45) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3047481 | 0.94 | PRCP (0.37) | KCNH2PRCPHCRTR1HCRTR2 | |
| SCHEMBL3057210 | 0.94 | PRCP (0.37) | KCNH2PRCPHCRTR1HCRTR2 | |
| SCHEMBL2278820 | 0.92 | KCNH2 (0.48) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2276767 | 0.92 | KCNH2 (0.48) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3054614 | 0.92 | KCNH2 (0.45) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3055605 | 0.92 | KCNH2 (0.45) | KCNH2PRCPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2276860 | 0.91 | HCRTR1 (0.39) | KCNH2PRCPHCRTR1HCRTR2 | |
| SCHEMBL2276865 | 0.91 | HCRTR1 (0.39) | KCNH2PRCPHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | claimed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2398794-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNH2 4523/4885PRCP 190/4885CYP3A4 1107/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNH2 4523/4885PRCP 190/4885CYP3A4 1107/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | KCNH2 4523/4885PRCP 190/4885CYP3A4 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.